Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III Sells 9,233 Shares

Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) CEO James F. Oliviero III sold 9,233 shares of Checkpoint Therapeutics stock in a transaction that occurred on Friday, February 7th. The shares were sold at an average price of $3.41, for a total transaction of $31,484.53. Following the transaction, the chief executive officer now directly owns 3,785,350 shares of the company’s stock, valued at approximately $12,908,043.50. This trade represents a 0.24 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Checkpoint Therapeutics Stock Performance

Checkpoint Therapeutics stock opened at $3.13 on Wednesday. The stock has a market capitalization of $152.84 million, a P/E ratio of -1.70 and a beta of 1.36. The company’s fifty day moving average price is $3.39 and its 200 day moving average price is $2.99. Checkpoint Therapeutics, Inc. has a 1 year low of $1.38 and a 1 year high of $4.50.

Checkpoint Therapeutics (NASDAQ:CKPT) last announced its earnings results on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.15) by ($0.08). Sell-side analysts predict that Checkpoint Therapeutics, Inc. will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Checkpoint Therapeutics

Several institutional investors have recently bought and sold shares of CKPT. Virtu Financial LLC acquired a new position in shares of Checkpoint Therapeutics during the third quarter valued at approximately $30,000. SBI Securities Co. Ltd. purchased a new stake in shares of Checkpoint Therapeutics during the fourth quarter worth approximately $32,000. PUREfi Wealth LLC acquired a new position in Checkpoint Therapeutics in the 4th quarter valued at $32,000. Bartlett & CO. Wealth Management LLC lifted its holdings in Checkpoint Therapeutics by 375.0% in the 4th quarter. Bartlett & CO. Wealth Management LLC now owns 19,000 shares of the company’s stock valued at $61,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. purchased a new position in Checkpoint Therapeutics in the 4th quarter valued at $64,000. 22.00% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several analysts recently commented on CKPT shares. HC Wainwright restated a “buy” rating and set a $20.00 price target on shares of Checkpoint Therapeutics in a research report on Monday, December 16th. D. Boral Capital started coverage on Checkpoint Therapeutics in a research report on Monday, January 13th. They set a “buy” rating and a $9.00 target price on the stock. Finally, Lake Street Capital lifted their price target on Checkpoint Therapeutics from $4.00 to $7.00 and gave the company a “buy” rating in a research note on Monday, December 16th.

Checkpoint Therapeutics Company Profile

Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.